SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated June 28, 2021, covers the results of BioSig Technologies, Inc.'s 2021 Annual Meeting of Stockholders. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and shareholder voting results rather than financial performance data.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved the Ninth Amendment to the 2012 Equity Incentive Plan, increasing the number of shares available for issuance by 2,500,000. The total pool of shares available under the plan is now 14,474,450.
- Board Elections: Seven directors were elected to serve until the 2022 annual meeting: Kenneth L. Londoner, Jeffrey F. O'Donnell, Sr., David Weild IV, Patrick J. Gallagher, Donald E. Foley, Anthony Zook, and Samuel E. Navarro.
- Auditor Ratification: Stockholders ratified the appointment of Friedman LLP as the independent registered public accounting firm for the 2021 fiscal year.
Voting Results and Shareholder Engagement
A total of 32,143,531 votes were cast by common stockholders, with an additional 50,524 votes from Series C Convertible Preferred Stock holders. Key voting outcomes included:
- Director Elections: All seven nominees received a plurality of votes cast. Broker non-votes totaled 7,686,979 for each director nominee.
- Equity Plan Amendment: Approved with 11,622,832 votes "For," 3,949,935 "Against," and 155,018 "Abstain."
- Auditor Ratification: Overwhelmingly approved with 23,166,600 votes "For," 177,457 "Against," and 70,707 "Abstain."
Outlook, Risks, and Management Commentary
The filing contains no specific management commentary regarding future financial guidance, operational outlook, or new risk factors. The document serves as a procedural record of the Annual Meeting outcomes. The full text of the 2012 Plan Amendment is referenced as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the impact of the 2.5 million share increase on potential future dilution.
- Review the 2021 Proxy Statement (filed April 30, 2021) for detailed terms of the Equity Incentive Plan Amendment.
- Confirm the composition of the newly elected Board of Directors and their tenure terms.
- Note the significant number of broker non-votes (7,686,979) regarding director elections, indicating shares held in street name where brokers lacked discretionary voting power.